Search research articles
Contact Us
Filters
Showing results (91-100 of 114) with videos related to
Page
of 12
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
May 14, 2025
Risk prediction for ALS using semi-competing risk models with applications to the ALS Natural History Consortium dataset
Andres Arguedas, David Schneck, Erjia Cui, et al.
Cell Systems
|
December 20, 2016
A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease
Nicholas T Seyfried, Eric B Dammer, Vivek Swarup, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|
January 5, 2012
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
Markus Otto, Robert Bowser, Martin Turner, et al.
Plos One
|
April 25, 2013
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis
James D Berry, Jeremy M Shefner, Robin Conwit, et al.
Lancet (London, England)
|
March 4, 2014
Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial
Anne-Marie Wills, Jane Hubbard, Eric A Macklin, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)
Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 14, 2025
ALSUntangled #78: Zinc
Benjamin Helmold, George Nathaniel, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 15, 2022
ALSUntangled #67: rituximab
Xiaoyan Li, Carmel Armon, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials
Angela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 114) with videos related to
Sort By:
Page
of 12
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
May 14, 2025
Risk prediction for ALS using semi-competing risk models with applications to the ALS Natural History Consortium dataset
Andres Arguedas, David Schneck, Erjia Cui, et al.
Cell Systems
|
December 20, 2016
A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease
Nicholas T Seyfried, Eric B Dammer, Vivek Swarup, et al.
Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
|
January 5, 2012
Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
Markus Otto, Robert Bowser, Martin Turner, et al.
Plos One
|
April 25, 2013
Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis
James D Berry, Jeremy M Shefner, Robin Conwit, et al.
Lancet (London, England)
|
March 4, 2014
Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial
Anne-Marie Wills, Jane Hubbard, Eric A Macklin, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
November 6, 2025
ALSUntangled #81: Pyridostigmine (mestinon<sup>®</sup>)
Nadia Mansoor, Terry Heiman-Patterson, Eva L Feldman, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
March 14, 2025
ALSUntangled #78: Zinc
Benjamin Helmold, George Nathaniel, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
September 15, 2022
ALSUntangled #67: rituximab
Xiaoyan Li, Carmel Armon, Paul Barkhaus, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|
February 24, 2024
The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials
Angela Genge, Jesse M Cedarbaum, Jeremy Shefner, et al.
The New England Journal of Medicine
|
July 9, 2020
Phase 1-2 Trial of Antisense Oligonucleotide Tofersen for <i>SOD1</i> ALS
Timothy Miller, Merit Cudkowicz, Pamela J Shaw, et al.
Page
of 12